1993-2023 Yılları Arasında Osteosarkomda Mezenkimal Kök-Hücre Kaynaklı Tedavi: Bibliyometrik Çalışma

Yıl 2025, Cilt: 20 Sayı: 1, 71 - 77

Akif Mirioğlu

Öz

Amaç: Osteosarkom, ergenlik ve çocukluk çağında görülme sıklığı yüksek olan kötü huylu bir kemik tümörüdür. Osteosarkom tedavisi kemoterapi, radyoterapi ve ortopedik cerrahiyi içeren uzun ve zorlu bir süreçtir. Kök hücre kaynaklı tedavi de osteosarkomda son zamanlarda çalışılmaktadır. Bu bibliyometrik çalışmada, osteosarkom ve kök hücre kaynaklı tedavi arasındaki araştırma eğilimini aydınlatmayı amaçladık.
Materiyal ve Metod: Osteosarkom ile ilgili yayınlar Web of Science Core Collection'dan alınmıştır. Veri analizi için R studio yazılımı ve VOS viewer analiz programı kullanılmıştır.
Bulgular: Yapılan analizde 853 yayın olduğu ve her yılla ortalama 7,7 yayın düşmekteydi. En üretken ülkeler ilk sırayı ABD ve ikinci sırayı Çin olmıştır. WoS'ta tanımlanan kategorik sınıflandırmaya göre, onkoloji (%41,7) ve hücre biyolojisi (%18,1) tanı ve tedavi açısından ilk iki alan olurken, patoloji (%3,7) ve ortopedi (%2,2) daha düşük çalışma seviyelerine sahipti. Ancak, en çok atıf alan yazar Gibbs idi. (USA; University of Florida University of Alberta UF Orthopedic & Sports Med Inst). “cancer stem cell”, “bone cancer” ve “mesenchymal stem cell” anahtar kelimelerinin osteosarkomla güçlü bağlantıları olduğu belirlenmiştir. Bunun yanında, Cancer Res. en çok atıf alan dergi olduğu belirlenmiştir.
Sonuç: Sonuç olarak, hücre kaynaklı tedavi ile osteosarkom arasında güçlü bir ilişki ortaya koyan ilişki araştırmasıyla olan bağlantıların son yıllarda artış gösterdiği tespit edildi.

Anahtar Kelimeler

Osteosarcoma, kök hücre, bibliyometri

Proje Numarası

yok

Mesenchymal stem-cell derived treatment in osteosarcoma between 1993-2023: Bibliometric study

Öz

Objective: Osteosarcoma is a malignant bone tumor with a high incidence in adolescence and childhood. Treatment is long and difficult, including chemotherapy, radiotherapy, and orthopedic surgery. Stem cell-derived treatment has also recently been studied in osteosarcoma. In this bibliometric study, we aimed to illuminate the trend of research between osteosarcoma and stem cell-derived treatment.

Materials and Methods: Publications on osteosarcoma were retrieved from the Web of Science Core Collection. R studio software and the VOS viewer analysis program were used for data analysis.

Results: There were 853 publications with an average of 7.7 publications per year. The most productive countries were the USA and China respectively. According to the categorical classification described in the WoS, oncology (41.7%), and cell biology (18.1%) were the first two fields in terms of diagnosis and treatment, while pathology (3.7%) and orthopedics (2.2%) had lower levels of work. However, the most cited author locally was Gibbs from the University of Florida University of Alberta UF Orthopedic & Sports Med Inst. in the USA. The keywords “cancer stem cell”, “bone cancer”, and “mesenchymal stem cell” had been determined to have strong links to osteosarcoma. Cancer Res was the most cited journal.

Conclusion: As a result, it has been found that research presenting strong links to the relationship between cell-derived therapy and osteosarcoma has shown an increase in recent years.

Anahtar Kelimeler

Stem cells, Osteosarcoma, Bibliometrics

Etik Beyan

Yok

Destekleyen Kurum

Yok

Proje Numarası

yok

Teşekkür

yok

Kaynakça

• Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol. 2021;28(3):119-138.
• Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012;118(23):5888-93.
• Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600-6.
• Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J immunother Cancer. 2015; 3(21).
• Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1-10.
• Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201-217.
• Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189-195.
• Bozkurt, AS. Publication status of mouse embryonic fibroblast cells in scientific journals. European Journal of Therapeutics.2021;27(2):135–141.
• Van Eck, NJ, Waltman L. (2014). Visualizing Bibliometric Networks. In: Ding, Y., Rousseau, R., Wolfram, D. (eds) Measuring Scholarly Impact. Springer, Cham.
• Yin MC, Wang HS, Yang X, Xu CQ, Wang T, Yan YJ, et al. Bibliometric Analysis and Visualization of Current Research Trends in Chinese Medicine for Osteosarcoma. Chin J Integr Med. 2022;28(5):445-452.
• Kramer K, Hicks DG, Palis J, Rosier RN, Oppenheimer J, Fallon MD, et al. Epithelioid osteosarcoma of bone. Immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm. Cancer. 1993; 71(10):2977-82.
• Coronado RA, Wurtzel WA, Simon CB, Riddle DL, George SZ. Content and bibliometric analysis of articles published in the Journal of Orthopaedic & Sports Physical Therapy. J Orthop Sports Phys Ther. 2011;41(12):920-931.
• Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7(11):967-76.
• Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64(5):1751-6.
• Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, Ghivizzani SC, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009;69(14):5648-55.
• Jiang ZY, Liu JB, Wang XF, Ma YS, Fu D. Current Status and Prospects of Clinical Treatment of Osteosarcoma. Technol Cancer Res Treat. 2022;21:15330338221124696.
• Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189-195.
• Singla A, Wang J, Yang R, Geller DS, Loeb DM, Hoang BH. Wnt Signaling in Osteosarcoma. Adv Exp Med Biol. 2020;1258:125-139.